Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826742 · ClinicalTrials.gov registry record · Phase 4
Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06826742: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT06826742 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06826742, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.
Interventions
- DRUG Intrathecal Morphine
- DRUG Intravenous line (IV) Methadone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06826742
The ClinicalTrials.gov registry entry for NCT06826742 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intrathecal Morphine is the first listed.
NCT06826742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06826742 about?
NCT06826742 is a clinical study titled "Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery". The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.
What is the current status of trial NCT06826742?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-02-12. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06826742?
The interventions under investigation include: Intrathecal Morphine (DRUG), Intravenous line (IV) Methadone (DRUG).
Who is sponsoring clinical trial NCT06826742?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.